Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer
ESMO Open · 2024-12 · 9 (12) · 103997
DOI: 10.1016/j.esmoop.2024.103997 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ESMO Open, 2024-12. Verfasst von K Fanucci und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Class I Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA. Electronic address: https://twitter.com/Kristina…
- Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA. Electronic address: https://twitter.com/antgiord…
- Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA. Electronic address: https://twitter.com/DrTimothyErick.
- Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA. Electronic address: https://twitter.com/stolaney…
- Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA. Electronic address: sarahl_sammons@dfci.harvard.…
Zitieren
APA
Fanucci, K., Giordano, A., Erick, T., Tolaney, S. M., & Sammons, S. (2024). Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer. ESMO Open, 9(12), 103997. https://doi.org/10.1016/j.esmoop.2024.103997
Vancouver
Fanucci K, Giordano A, Erick T, Tolaney SM, Sammons S. Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer. ESMO Open. 2024;9(12):103997. doi:10.1016/j.esmoop.2024.103997
BibTeX
@article{Fanucci2024,
author = {Fanucci, K and Giordano, A and Erick, T and Tolaney, S M and Sammons, S},
title = {Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer},
journal = {ESMO Open},
year = {2024},
volume = {9},
number = {12},
pages = {103997},
doi = {10.1016/j.esmoop.2024.103997}
}
EUVIMED